Pharyngeal Antisepsis to Reduce COVID-19 Pneumonia.

Davidson, Bruce L; Tapson, Victor F; Irwin, Richard S; French, Cynthia L; Elliott, C Gregory; Levi, Marcel

Davidson, Bruce L; Tapson, Victor F; Irwin, Richard S; French, Cynthia L; Elliott, C Gregory; Levi, Marcel.

Afiliação

Davidson BL; Pulmonary Medicine, Providence Health System, Seattle, Wash. Electronic address: brucedavidson@pobox.com.
Tapson VF; Pulmonary and Critical Care Medicine, Cedars-Sinai Medical Center, Los Angeles, Calif.
Irwin RS; Pulmonary and Critical Care Medicine, University of Massachusetts Medical School and UMass Memorial Medical Center, Worcester.
French CL; University of Massachusetts Medical School and Graduate School of Nursing, Worcester.
Elliott CG; Pulmonary Medicine, Intermountain Healthcare and University of Utah School of Medicine, Murray.
Levi M; University College London Hospitals NHS Foundation Trust and Cardiometabolic Programme-NIHR UCLH/UCL BRC, London, UK.

Am J Med ; 134(3): 297-298, 2021 03.

Article em En | MEDLINE | ID: mdl-33338507

Assuntos

Antissepsia/métodos; COVID-19; Antissépticos Bucais/uso terapêutico; Nasofaringe/virologia; Pneumonia Viral; SARS-CoV-2; Infecções Assintomáticas/terapia; COVID-19/prevenção & controle; COVID-19/terapia; COVID-19/virologia; Controle de Doenças Transmissíveis/métodos; Humanos; Pneumonia Viral/etiologia; Pneumonia Viral/prevenção & controle; SARS-CoV-2/efeitos dos fármacos; SARS-CoV-2/isolamento & purificação

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 4_TD Base de dados: MEDLINE Assunto principal: Pneumonia Viral / Antissepsia / Nasofaringe / SARS-CoV-2 / COVID-19 / Antissépticos Bucais Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Revista: Am J Med Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google